A Comparison of Cornell and Sokolow-Lyon Electrocardiographic Criteria for Left Ventricular Hypertrophy in Korean Patients

다국어 초록 (Multilingual Abstract)

Background and Objectives: Electrocardiography (ECG) is a cost-effective and useful method for diagnosing left ventricular hypertrophy (LVH) in a large-scale study or in clinical practice. Among ECG criteria, the Cornell product (Cor P) and Sokolow-Lyon criteria were adopt-ed by the European Society of Hypertension-European Society of Cardiology Guidelines but have different performances among races.
The aim of this study was to compare the diagnostic performance of two voltage criteria in Korean patients.
Subjects and Methods: Electrocardiography and echocardiographic LV mass of 332 (159 male, 173 female) consecutive patients were analyzed. Cornell voltage criteria and the Cor P were compared with Sokolow-Lyon voltage (Sok V) and the Sokolow-Lyon product (Sok P).
The sensitivities and specificities were estimated using a receiver-operating characteristics (ROC) curve in relation to the LVH diagnosis.
The sensitivities and revised cut-off values were derived at specificity levels of 90, 95, and 100%.
Results: The Cornell-based criteria generally showed better performance than that of the Sok V criteria and Sok P in the area under the ROC curve analysis. The revised cut-off values for the Cornell voltage criteria (20 and 16 mm for males and females, respectively) showed an improved sensitivity (19.7 and 30.3% for males and females, respectively), with a high specificity of 95%.
Conclusion: The Cornell-based criteria had better performance than that of the Sokolow-Lyon criteria in both Korean men and women.
However, revised cut-off values are needed to improve accuracy.

참고문헌 (Reference)

1 Sokolow M, "The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads" 37 : 161-186, 1949

2 Hotelling H, "The selection of variates for use in prediction with some comments on the general problem of nuisance parameters" 11 : 271-283, 1940

3 Bluemke DA, "The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) Study" 52 : 2148-2155, 2008

4 Hense HW, "The associations of body size and body composition with left ventricular mass: impacts for indexation in adults" 32 : 451-457, 1998

5 Pewsner D, "Ruling a diagnosis in or out with “SpPIn” and “SnNOut”: a note of caution" 329 : 209-213, 2004

6 Rodrigues SL, "Revision of the Sokolow-Lyon-Rappaport and cornell voltage criteria for left ventricular hypertrophy" 90 : 46-53, 2008

7 Okin PM, "Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study" 108 : 684-690, 2003

8 Sahn DJ, "Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements" 58 : 1072-1083, 1978

9 Lang RM, "Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology" 18 : 1440-1463, 2005

10 Truong QA, "Performance of electrocardiographic criteria for left ventricular hypertrophy as compared with cardiac computed tomography: from the Rule Out Myocardial Infarction Using Computer Assisted Tomography Trial" 28 : 1959-1967, 2010

11 De Simone G, "Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Study" 18 (18): 191-196, 2005

12 Alfakih K, "New gender-specific partition values for ECG criteria of left ventricular hypertrophy: recalibration against cardiac MRI" 44 : 175-179, 2004

13 Noble LM, "Left ventricular hypertrophy in left bundle branch block" 17 : 157-160, 1984

14 Casale PN, "Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings" 75 : 565-572, 1987

15 Schillaci G, "Improved electrocardiographic diagnosis of left ventricular hypertrophy" 74 : 714-719, 1994

16 Barrios V, "Gender differences in the diagnosis and treatment of left ventricular hypertrophy detected by different electrocardiographic criteria: findings from the SARA Study" 25 : 51-56, 2010

17 Okin PM, "Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE Study. Losartan Intervention For Endpoint" 15 : 663-671, 2002

18 Lee YW, "Electrocardiographic diagnosis of left ventricular hypertrophy by scoring system" 7 : 1-8, 1977

19 Casale PN, "Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria" 6 : 572-580, 1985

20 Devereux RB, "Electrocardiographic detection of left ventricular hypertrophy using echocardiographic determination of left ventricular mass as the reference standard. Comparison of standard criteria, computer diagnosis and physician interpretation" 3 : 82-87, 1984

21 Molloy TJ, "Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product" 20 : 1180-1186, 1992

22 Devereux RB, "Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings" 57 : 450-458, 1986

23 Sundström J, "Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men" 103 : 2346-2351, 2001

24 Xie L, "Correlation between echocardiographic left ventricular mass index and electrocardiographic variables used in left ventricular hypertrophy criteria in Chinese hypertensive patients" 51 : 391-401, 2010

25 Verdecchia P, "Comparison of electrocardiographic criteria for diagnosis of left ventricular hypertrophy in hypertension: the MAVI Study" 1 : 207-215, 2000

26 Dahlöf B, "Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol" 359 : 995-1003, 2002

27 Okin PM, "Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention for Endpoint Reduction (LIFE) in Hypertension Study. The Life Study Investigators" 36 : 766-773, 2000

28 Pewsner D, "Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review" 335 : 711-, 2007

29 Hancock EW, "AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part V: electrocardiogram changes associated with cardiac chamber hypertrophy: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology" 53 : 992-1002, 2009

30 Mancia G, "2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)" 25 : 1105-1187, 2007